AIM ImmunoTech
AIM ImmunoTech company logo. | |
| AIM | |
| AMEX: AIM | |
| Industry | Biopharmaceutical |
| Headquarters | , |
Key people | CEO Thomas K. Equels, J.D. COO Peter W. Rodino III, J.D. CFO Ellen Lintal |
| Products | Ampligen Alferon |
| Services | Cancer and immunotherapy research |
| Total assets | $ 64.584 million (2020) |
AIM ImmunoTech Inc., formerly known as Hemispherx Biopharma Inc., is a biopharmaceutical company based in Ocala, Florida that is focused on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders. Founded in 1990, the company has twenty-three employees.
The company has created an immunomodulatory double stranded RNA drug called Ampligen.
It is also developing Ampligen to use as a treatment for multiple cancer tumor types, COVID-19 and chronic fatigue syndrome.